Categories: DevelopmentDrug
Zymedi is a new drug development company based on protein synthetase and is developing treatments for intractable diseases such as pulmonary arterial hypertension
Investors 1
Mentions in press and media 3
| Date | Title | Description |
| 08.12.2025 | Zymedi Announces "rapaprutug" as the International Nonproprietary Name (INN) for ZMA001 | INCHEON, South Korea, Dec. 8, 2025 /PRNewswire/ -- Zymedi (CEO Sunghoon Kim) announced that the World Health Organization (WHO) has assigned rapaprutug as the International Nonproprietary Name (INN) for the company's first-in-class antibody... |
| 31.07.2024 | FDA Grants Orphan Drug Designation (ODD) Status to Zymedi's ZMA001 for Pulmonary Arterial Hypertension | INCHEON, South Korea, July 31, 2024 /PRNewswire/ -- Zymedi (CEO Sunghoon Kim) announced that its first-in-class antibody treatment ZMA001, currently in development for pulmonary arterial hypertension (PAH), has been designated as an Orphan ... |
| 08.02.2024 | First in Human Dosed in Clinical Trial of ZMA001 for Treatment of Pulmonary Arterial Hypertension (PAH) | INCHEON, South Korea, Feb. 8, 2024 /PRNewswire/ -- Zymedi announced today that the first in human dosage of ZMA001, a monoclonal antibody being developed as a first-in-class treatment for Pulmonary Arterial Hypertension (PAH) has been initi... |
Reviews 0
